Pharmaceuticals

Latest KFF Health News Stories

KHN’s ‘What The Health?’: Tennessee Seeks Medicaid Changes

KFF Health News Original

Tennessee wants to convert its Medicaid program to a block grant. But is its plan legal? Meanwhile, Congress continues to struggle with legislation to rein in prescription drug prices and surprise medical bills. This week, Anna Edney of Bloomberg News, Jennifer Haberkorn of the Los Angeles Times and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss these issues and more. Rovner also interviews Dr. Marty Makary, author of the new book “The Price We Pay” about why health care costs so much.

Purveyors Of Black-Market Pharmaceuticals Target Immigrants

KFF Health News Original

Illegal medications, sold in immigrant communities around the United States, can cause serious harm to consumers, authorities say. Law enforcement officers are cracking down, but some think more must be done.

KHN’s ‘What The Health?’: Despite Booming Economy, Uninsured Rate Ticks Up

KFF Health News Original

Nearly 2 million more Americans were uninsured in 2018 than in the previous year, according to the Census Bureau’s annual report. Plus, the Trump administration announced plans to ban flavored vape liquids, and Congress is back and working to address high prescription drug prices and “surprise” medical bills. This week, Joanne Kenen of Politico, Tami Luhby of CNN and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.

In India’s Slums, ‘Painkillers Are Part Of The Daily Routine’

KFF Health News Original

As the Indian government reluctantly loosens its prescription opioid laws after decades of lobbying by palliative care advocates desperate to ease their patients’ pain, the nation’s sprawling, cash-fed health care system is ripe for misuse.

Beset By Lawsuits And Criticism In U.S., Opioid Makers Eye New Market In India

KFF Health News Original

What began in India as a populist movement to bring inexpensive morphine to the diseased and dying poor has paved the way for a booming pain management industry. Now, new customers are being funneled to U.S. drugmakers bedeviled by a government crackdown back home.